Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Erin A Kuether"'
Autor:
Hartmut Weiler, Juan Fang, Qizhen Shi, Robert R. Montgomery, David A. Wilcox, Jocelyn A. Schroeder, Erin A Kuether, Weiqing Jing
Publikováno v:
J Thromb Haemost
BACKGROUND: Rotational thromboelastometry (ROTEM) has been commonly used to assess the viscoelastic properties of the blood clotting process in the clinic for patients with a hemostatic or prothrombotic disorder. OBJECTIVE: To evaluate the capability
Autor:
Erin L. Kuether, Scot A. Fahs, Qizhen Shi, Robert R. Montgomery, Yingyu Chen, Jocelyn A. Schroeder
Publikováno v:
Blood. 123:395-403
Our previous studies have demonstrated that platelet FVIII (2bF8) gene therapy can improve hemostasis in hemophilia A mice, even in the presence of inhibitory antibodies, but none of our studies has targeted human cells. Here, we evaluated the feasib
Publikováno v:
Molecular Therapy. 22:169-177
Here, we developed a clinically translatable platelet gene therapy approach for hemophilia B. Platelet-targeted FIX (2bF9) expression was introduced by transplantation of hematopoietic stem cells (HSCs) transduced with 2bF9 lentivirus (LV). Sustained
Autor:
J. Cox Gill, Qizhen Shi, Erin L. Kuether, Jocelyn A. Schroeder, Robert R. Montgomery, Scot A. Fahs, C. L. Perry
Publikováno v:
Journal of Thrombosis and Haemostasis. 10:2328-2337
Summary. Background: The important association between von Willebrand factor (VWF) and factor VIII (FVIII) has been investigated for decades, but the effect of VWF on the reactivity of FVIII inhibitory antibodies, referred to as inhibitors, is still
Autor:
Jocelyn A. Schroeder, Scot A. Fahs, Erin L. Kuether, Robert R. Montgomery, Jerry Ware, Sachiko Kanaji, Qizhen Shi
Publikováno v:
Molecular Therapy. 20:625-632
Bernard-Soulier syndrome (BSS) is an inherited bleeding disorder caused by a defect in the platelet glycoprotein (GP) Ib-IX-V complex. The main treatment for BSS is platelet transfusion but it is often limited to severe bleeding episodes or surgical
Publikováno v:
Haemophilia. 18:639-646
Intravenous infusion studies in humans suggest that both von Willebrand factor (VWF) and factor VIII (FVIII) remain intravascular in contrast to other coagulation proteins. We explored whether infusion of VWF and FVIII by either intraperitoneal (i.p.
Autor:
Erin L. Kuether, Qizhen Shi, Hartmut Weiler, Brian C. Cooley, Scot A. Fahs, Robert R. Montgomery
Publikováno v:
Blood. 116:3049-3057
The natural cell type(s) that synthesize and release factor VIII (FVIII) into the circulation are still not known with certainty. In vitro studies indicate that artificial expression of FVIII in endothelial cells produces an intracellular pool of FVI
Autor:
Christopher E. Walsh, Qizhen Shi, Erin L. Kuether, Guowei Zhang, Scot A. Fahs, Robert R. Montgomery
Publikováno v:
Blood. 116:1235-1243
We developed 2bF9 transgenic mice in a hemophilia B mouse model with the expression of human factor IX (FIX) under control of the platelet-specific integrin αIIb promoter, to determine whether ectopically expressing FIX in megakaryocytes can enable
Autor:
Erin L. Kuether, David A. Wilcox, Scot A. Fahs, Patricia A. Morateck, Hartmut Weiler, Robert R. Montgomery, Nicole Mareno, Qizhen Shi
Publikováno v:
Blood. 112(7)
Although genetic induction of factor VIII (FVIII) expression in platelets can restore hemostasis in hemophilia A mice, this approach has not been studied in the clinical setting of preexisting FVIII inhibitory antibodies to determine whether such ant
Autor:
Erin L. Kuether, Jocelyn A. Schroeder, Robert R. Montgomery, Yingyu Chen, Guowei Zhang, Qizhen Shi
Publikováno v:
Blood. 120:1101-1101
Abstract 1101 While data from the clinical trials using AAV vector expression FIX in hemophilia B gene therapy in humans are very encouraging, for individuals with severe liver disease or neutralizing antibodies to AAV, an alternative gene therapy ap